<DOC>
	<DOCNO>NCT00319709</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety SR58611A elderly patient depression.The primary objective evaluate efficacy 700 mg dose SR58611A compare placebo elderly patient depression . The secondary objective evaluate safety SR58611A evaluate efficacy SR58611A disability quality life elderly patient depression .</brief_summary>
	<brief_title>An Eight-Week Study Evaluate Efficacy Safety SR58611A Elderly Patients With Depression</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Amibegron</mesh_term>
	<criteria>Outpatients inpatient Major Depressive Disorder ( MDD ) recurrent Major Depressive Episode ( MDE ) accord DSM IVTR criterion . MADRS score equal 22 . Patients current significant risk suicide investigator 's clinical judgment . The duration current depressive episode great 2 year . Patients whose current depressive episode secondary general medical condition Patients lifetime history accord MINI screening : bipolar disorder , psychotic disorder , antisocial personality disorder . Patients current history accord MINI screening anxiety disorder , alcohol dependence abuse substance dependence abuse Patients severe unstable concomitant medical condition . History seizure single childhood febrile seizure . Patients abnormal thyroid functioning . Patients clinically significant ECG finding screen . Patients take investigational drug last 3 month prior screen . Any subject previously participate SR58611A protocol . Patients MiniMental State Examination ( MMSE ) score &lt; 25 screening .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>depression</keyword>
	<keyword>antidepressive agent</keyword>
	<keyword>control clinical trial</keyword>
</DOC>